Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 12/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24592610 | 0.92 | NLRP3 (0.58) | NLRP3CA2CA1KMT2A | |
| SCHEMBL19518993 | 0.88 | NLRP3 (0.54) | NLRP3CA2KMT2A | |
| SCHEMBL19519058 | 0.87 | NLRP3 (0.66) | NLRP3CA2 | |
| SCHEMBL19519040 | 0.86 | NLRP3 (0.74) | NLRP3CA2 | |
| SCHEMBL19475370 | 0.85 | NLRP3 (0.54) | NLRP3CA2 | |
| SCHEMBL19519054 | 0.85 | NLRP3 (0.51) | NLRP3CA2KMT2A | |
| SCHEMBL23378793 | 0.84 | GSTO1 (0.52) | NLRP3CA2 | |
| SCHEMBL19518977 | 0.83 | NLRP3 (0.49) | NLRP3CA2 | |
| SCHEMBL23957303 | 0.82 | NLRP3 (0.50) | NLRP3CA2 | |
| SCHEMBL23378794 | 0.82 | NLRP3 (0.48) | NLRP3CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-3445756-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184623-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885CA2 2191/4885CA1 4294/4885 |
| US-20190119203-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885CA2 2191/4885CA1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.